Illumina to acquire proteomics company SomaLogic in $425 million all cash deal
HQ Team June 23, 2025: Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 23, 2025: Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a.
HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.
HQ Team June 22, 2025: Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, as.
HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.
HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.
HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.
HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.
HQ Team June 13, 2025: The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between.
HQ Team July 13, 2025: Rein Therapeutics, Inc., has paused its enrollment and patient dosing at its US clinical trial sites testing a.
HQ Team June 13, 2025: UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been.